Liaoyuan Hu, Ph.D.CEO at ReCentrics Bio
Dr. Liaoyuan Hu is currently the CEO and cofounder of ReCentrics Bio., a startup company focused on developing therapeutic antibodies against GPCR targets for the treatment of diseases with unmet medical need. Before founding ReCentrics, Liaoyuan worked as a Scientific Director, Head of in vitro Pharmacology at Amgen Asia R&D Center, where he directed the effort to build various technology platforms to support Amgen innovative drug discovery. Prior to joining Amgen, Liaoyuan served in a variety of discovery-focused roles at Eli Lilly China R&D Center and Lexicon Pharmaceutics, and was responsible for target validation, early candidate identification and characterization for drug discovery programs. Liaoyuan earned his Ph.D degree from University of Texas Medical Branch at Galveston and did his postdoctoral training on GPCR signaling transduction in Dr. Lefkowitz’s lab at Duke University.